drugset / Trial / NCT02922686

Penicillin for the Emergency Department Outpatient Treatment of CELLulitis

NCT02922686

RandomizedParallel-groupDouble-blindTreatment

Summary

The main objective of this study is to investigate the non-inferiority of oral flucloxacillin alone compared with a combination of oral flucloxacillin and phenoxymethylpenicillin for the emergency department directed outpatient treatment of cellulitis, wound infections and abscesses, recently renamed by the Food and Drug Administration (FDA) as acute bacterial skin and skin structure infections (ABSSSIs). Half of the trial participants will receive flucloxacillin and placebo in combination, and the remaining half will be treated will flucloxacillin and phenoxymethylpenicillin. In a secondary objective the trial aims to measure adherence and persistence of trial patients with outpatient antibiotic therapy. In addition a within-trial evaluation of the cost per quality adjusted life year (QALY) gained from the use of oral flucloxacillin compared with combination therapy from the perspective of the health-care payer (direct costs) the patient and government. Finally the study will externally validate the Extremity Soft Tissue Infection-score, a Health Related Quality of Life (HRQL) questionnaire designed to quantify the impact of cellulitis, wound infections and abscesses on patient HRQL in clinical trials.

Timeline

Start
2016-12
Primary completion
2019-12
Completion
2019-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator FLOXACILLIN Small molecule 500 mg Oral
Comparator Penicillin V Small molecule 500 mg Oral